TN HB0413

Allows patients with severe chronic diseases or terminal illnesses to access investigational adult stem cell treatments that are in clinical trials but not yet FDA-approved

Requires physician attestation that FDA-approved treatments are unavailable or unlikely to help, along with a written recommendation for a specific stem cell treatment class

Mandates written informed consent before treatment, with parents, guardians, or conservators permitted to consent for minors or incapacitated patients

Prohibits the Board of Medical Examiners and Board of Osteopathic Examination from taking action against a physician's license solely for recommending investigational stem cell treatments that meet standard of care

Bars state and local government entities from interfering with eligible patients' access to authorized investigational stem cell treatments